Logo

Johnson & Johnson Receives the US FDA's EUA for COVID-19 Vaccine

Share this

Johnson & Johnson Receives the US FDA's EUA for COVID-19 Vaccine

Shots:

  • The FDA has issued a EUA for a single-shot COVID-19 vaccine to prevent COVID-19 in individuals aged ≥18yrs. The company plans to file BLA to the US FDA in 2021
  • The EUA is based on a P-III ENSEMBLE study that demonstrated 85% efficacy in preventing severe disease across all regions and protect against COVID-19 related hospitalization and death- across countries with different variants
  • The EUA follows a unanimous vote by the US FDA's VRBPAC on Feb 26- 2020. The company plans to deliver 100M doses to the US in the H1’21

 ­ Ref: PRNewswire | Image: Law.com

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions